体外膜氧合患者临床试验中一种新的纵向有序结局指标的开发
该研究在澳大利亚和新西兰28家医院的前瞻性多中心研究中,纳入2019年2月至2023年9月接受任何类型ECMO的成年ICU患者,开发并验证了DOSE(每日器官支持)纵向有序结局,该结局涵盖死亡、接受ECMO、通气但未接受ECMO、在ICU但未通气、在医院病房、出院6个等级。在1,375例患者中,第90天静脉-动脉ECMO、静脉-静脉ECMO或体外心肺复苏患者的死亡率分别为42%、29%和66%;DOSE可准确预测6个月死亡和新发残疾(曲线下面积>0.800)。模拟双臂临床试验中,每组400例、比值比1.20时,DOSE的统计效能比单独分析28天死亡率高56%(36% vs. 91%)。
要点
- DOSE结局包含6个等级:死亡、接受ECMO、通气但未接受ECMO、在ICU但未通气、在医院病房、出院。
- 在1,375例ECMO患者中,第90天静脉-动脉ECMO、静脉-静脉ECMO或体外心肺复苏患者的死亡率分别为42%、29%、66%。
- DOSE可准确预测6个月死亡和新发残疾,曲线下面积>0.800。
- 模拟双臂临床试验每组400例、比值比1.20时,DOSE的统计效能为91%,而单独分析28天死亡率为36%,DOSE提供56%更多效能。
适用人群与场景
- 2019年2月至2023年9月入住参与研究的ICU、接受任何类型ECMO的成年患者,来自澳大利亚和新西兰28家医院。
研究设计与关键结果
- 研究类型为前瞻性、多中心研究,在澳大利亚和新西兰28家医院开展,纳入1,375例接受ECMO的患者(中位年龄52岁;34%为女性)。
- DOSE结局的构建考虑:1)死亡,2)接受ECMO,3)通气但未接受ECMO,4)在ICU但未通气,5)在医院病房,6)出院。
- 第90天时,接受静脉-动脉ECMO、静脉-静脉ECMO或体外心肺复苏的患者中死亡者分别占42%、29%、66%。
- DOSE可准确预测6个月死亡和新发残疾,曲线下面积>0.800。
- 在每组400例、比值比1.20的模拟双臂临床试验中,DOSE的统计效能为91%,而单独分析28天死亡率的统计效能为36%,DOSE提供56%更多效能。
证据类型、等级与局限
- 证据类型:前瞻性、多中心研究。
- DOSE与消费者及其他利益相关者合作开发,并针对6个月死亡和新发残疾进行验证。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与28天死亡率相比,DOSE在模拟双臂临床试验中提供更多统计效能。
- 作者认为,DOSE与以患者为中心的结局相比表现良好。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Randomized clinical trials in intensive care often prioritize disease-focused outcomes rather than patient-centered outcomes. Objectives: To report and evaluate the DOSE (daily organ support for patients on extracorporeal membrane oxygenation [ECMO]) outcome. This is a new longitudinal ordinal outcome for clinical trials in patients receiving ECMO. Methods: A prospective, multicenter study was conducted at 28 hospitals in Australia and New Zealand. Adult patients admitted to participating ICUs between February 2019 and September 2023 who received any type of ECMO were included. The DOSE outcome was created considering 1) death, 2) receiving ECMO, 3) ventilated but not receiving ECMO, 4) in an ICU but not ventilated, 5) in a hospital ward, and 6) discharged from the hospital. DOSE was developed in collaboration with consumers and other stakeholders and validated against death and new disability at 6 months. Simulations were performed to compare the power obtained against 28-day mortality alone. Measurements and Main Results: Among 1,375 patients who received ECMO (median age, 52 yr; 34% women), at Day 90, 42%, 29%, and 66% of those receiving venoarterial, venovenous ECMO, or extracorporeal cardiopulmonary resuscitation were deceased, respectively. DOSE accurately predicted death and new disability at 6 months (area under the curve > 0.800). With a sample size of 400 patients per arm and an odds ratio of 1.20, DOSE provided 56% more power than an analysis considering 28-day mortality alone (36% vs. 91%) in simulations of a two-arm clinical trial. Conclusions: The DOSE outcome performed well compared with a patient-centered outcome. Compared with 28-day mortality, DOSE provided more statistical power in a simulated two-arm clinical trial.
参考来源
- Serpa Neto A, Higgins L, Lorenzi E, et al. Development of a New Longitudinal Ordinal Outcome for Clinical Trials in Extracorporeal Membrane Oxygenation Patients. Am J Respir Crit Care Med. 2025. PMID: 40153559. doi:10.1164/rccm.202408-1582OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。